Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors.

@article{DeTora2001RofecoxibSC,
  title={Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors.},
  author={Lisa M. DeTora and D. Santhi Krupa and Jim Bolognese and R. S. Sherwin'R. S. Spangler'M. A. Sperling and Elliot W. Ehrich},
  journal={The Journal of rheumatology},
  year={2001},
  volume={28 11},
  pages={2494-503}
}
OBJECTIVE To evaluate the efficacy of rofecoxib (Vioxx) in subpopulations of patients with osteoarthritis (OA) identified by demographic or baseline disease characteristics, or varied OA involvement. METHODS Data were combined from three 6-week double blind trials in patients with OA of the knee or hip. All trials contained placebo, 12.5 mg rofecoxib, and 25 mg rofecoxib arms (the only trials to date containing all 3 treatments). Analyses were performed on subgroups categorized according to… CONTINUE READING